ICTRP Search Portal

Main

Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.

Register:	JPRN
Last refreshed on:	17 October 2023
Main ID:	JPRN-UMIN000020543
Date of registration:	13/01/2016
Prospective Registration:	No
Primary sponsor:	National Hospital Organization Okayama Medical Center
Public title:	Efficacy of imatinib for the treatment of pulmonary veno-occlusive disease/pulmonary capillary hemangiomatosis
Scientific title:	Efficacy of imatinib for the treatment of pulmonary veno-occlusive disease/pulmonary capillary hemangiomatosis - Efficacy of imatinib for the treatment of pulmonary veno-occlusive disease/pulmonary capillary hemangiomatosis
Date of first enrolment:	2015/03/01
Target sample size:	8
Recruitment status:	Complete: follow-up complete
URL:	https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000023718
Study type:	Interventional
Study design:	Single arm Non-randomized
Phase:	Not applicable

Countries of recruitment
Japan

Contacts

Name:	Hiromi Matsubara
Address:	1711-1 Tamasu, Kita-ku, Okayama, JAPAN Japan
Telephone:	086-294-9911
Email:	himatsu@okayamamc.jp
Affiliation:	National Hospital Organization Okayama Medical Center Departments of Cardiology and Clinical Science

Name:	Hiromi Matsubara
Address:	1711-1 Tamasu, Kita-ku, Okayama, JAPAN Japan
Telephone:	086-294-9911
Email:	himatsu@okayamamc.jp
Affiliation:	National Hospital Organization Okayama Medical Center Departments of Cardiology and Clinical Science

Key inclusion & exclusion criteria

Inclusion criteria:
Exclusion criteria: Patients with a contraindication to imatinib Patients who were considered as inadequate for enrollment by the principal investigator

Age minimum: 18years-old
Age maximum: Not applicable
Gender: Male and Female

Health Condition(s) or Problem(s) studied

pulmonary veno-occlusive disease/pulmonary capillary hemangiomatosis

Intervention(s)

Oral administration of imatinib

Primary Outcome(s)

Efficacy (Time to clinical worsening)

Secondary Outcome(s)

Safety Efficacy (Median survival)

Secondary ID(s)

Source(s) of Monetary Support

None

Secondary Sponsor(s)

Ethics review

Status: YES
Approval date:
Contact:

Results

Results available:
Date Posted:
Date Completed:
URL:

Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.